Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
Delaunoit T, Van den Eynde M, Borbath I, Demetter P, Demolin G, Pattyn P, Pauwels S, Peeters M, Roeyen G, Van Cutsem E, Van Hootegem P, Van Laethem JL, Verslype C, Hendlisz A. Delaunoit T, et al. Among authors: van cutsem e, van hootegem p, van laethem jl, van den eynde m. Acta Gastroenterol Belg. 2009 Jan-Mar;72(1):49-53. Acta Gastroenterol Belg. 2009. PMID: 19402372 Review.
Adjuvant treatment for colorectal cancer.
Van Laethem JL. Van Laethem JL. Acta Gastroenterol Belg. 2001 Jul-Sep;64(3):263-7. Acta Gastroenterol Belg. 2001. PMID: 11680045 Review.
Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
Demols A, Peeters M, Polus M, Honoré P, Boterberg T, Gay F, Closon MT, Van Houtte P, Closset J, Van Laethem JL. Demols A, et al. Among authors: van houtte p, van laethem jl. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1351-6. doi: 10.1016/j.ijrobp.2005.01.043. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029792 Clinical Trial.
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
Personeni N, Hendlisz A, Gallez J, Galdon MG, Larsimont D, Van Laethem JL, Nagy N, Barette M, Paesmans M, Cardoso F, Bleiberg H. Personeni N, et al. Among authors: van laethem jl. Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62. doi: 10.1053/j.seminoncol.2005.04.029. Semin Oncol. 2005. PMID: 16399434
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Van Cutsem E, et al. Among authors: van laethem jl. J Clin Oncol. 2007 May 1;25(13):1658-64. doi: 10.1200/JCO.2006.08.1620. J Clin Oncol. 2007. PMID: 17470858 Clinical Trial.
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A. Tabernero J, et al. Among authors: van cutsem e, van laethem jl. J Clin Oncol. 2007 Nov 20;25(33):5225-32. doi: 10.1200/JCO.2007.13.2183. J Clin Oncol. 2007. PMID: 18024868 Clinical Trial.
266 results